'I no fit poo-poo from di normal place again after my colostomy surgery sake of cancer'
E mean say her colostomy na permanent one,- "I go dey poopoo from my stomach for di rest of my life," di doctors seal her anus. "Wen dem tell me say I no go dey fit defecate from my anus again, e bin ...
Canaccord maintains $180 target on Natera stock post-NCCN update
Canaccord Genuity maintained a Buy rating on Natera (NASDAQ:NTRA) shares, with a price target of $180. Trading at $169.27, the $22.35 billion market cap company enjoys strong analyst support, with a ...
Le Lézard1d
NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma
Natera, Inc. , a global leader in cell-free DNA and genetic testing, today commented on recent updates by the NCCN on circulating tumor DNA (ctDNA) molecular residual disease (MRD) testing in the ...
Natera comments on updated NCCN guidance for circulating tumor DNA
Natera (NTRA) commented on recent updates by the NCCN on circulating tumor DNA molecular residual disease testing in the Clinical Practice ...
Medscape2d
Radiation Intensification Enhances Response in Rectal Cancer
Radiation dose intensification improves pathologic complete response rates in locally advanced rectal cancer but also leads ...